International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia - data from the I-CAH registry.

OBJECTIVE Despite published guidelines no unified approach to hormone replacement in congenital adrenal hyperplasia (CAH) exists. We aimed to explore geographical and temporal variations in the treatment with glucocorticoids and mineralocorticoids in CAH. DESIGN This retrospective multi-center study, including 31 centers (16 countries), analyzed data from the International-CAH Registry. METHODS Data was collected from 461 patients aged 0-18 years with classic 21-hydroxylase deficiency (54.9% females) under follow-up between 1982 - 2018. Type, dose and timing of glucocorticoid and mineralocorticoid replacement was analyzed from 4174 patient visits. RESULTS The most frequently used glucocorticoid was hydrocortisone (87.6%). Overall, there were significant differences between age groups with regards to daily hydrocortisone-equivalent dose for body surface, with the lowest dose (median with interquartile range) of 12.0 (10.0 - 14.5) mg/ m2/ day at age 1 - 8 years and the highest dose of 14.0 (11.6 - 17.4) mg/ m2/ day at age 12-18 years. Glucocorticoid doses decreased after 2010 in patients 0-8 years (p<0.001) and remained unchanged in patients aged 8-18 years. Fludrocortisone was used in 92% of patients, with relative doses decreasing with age. A wide variation was observed among countries with regards to all aspects of steroid hormone replacement. CONCLUSIONS Data from the I-CAH Registry suggests international variations in hormone replacement therapy, with a tendency to treatment with high doses in children.

[1]  L. Hofbauer,et al.  Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency , 2020, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  H. Falhammar,et al.  Bone Mineral Density in Adults With Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis , 2020, Frontiers in Endocrinology.

[3]  V. Hasenmajer,et al.  Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy. , 2020, The Journal of endocrinology.

[4]  M. Bidlingmaier,et al.  Effect of androgen excess and glucocorticoid exposure on metabolic risk profiles in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  S. F. Ahmed,et al.  The Role of International Databases in Understanding the Aetiology and Consequences of Differences/Disorders of Sex Development , 2019, International journal of molecular sciences.

[6]  H. Falhammar,et al.  Glucocorticoid Regimens in the Treatment of Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis , 2019, Journal of the Endocrine Society.

[7]  T. Cheetham,et al.  Growth of patients with congenital adrenal hyperplasia due to 21-hydroxylase in infancy, glucocorticoid requirement and the role of mineralocorticoid therapy , 2018, Journal of pediatric endocrinology & metabolism : JPEM.

[8]  B. Walker,et al.  Plasma metabolomic profile varies with glucocorticoid dose in patients with congenital adrenal hyperplasia , 2017, Scientific Reports.

[9]  N. Krone,et al.  Cardiovascular health, growth and gonadal function in children and adolescents with congenital adrenal hyperplasia , 2016, Archives of Disease in Childhood.

[10]  P. Hindmarsh,et al.  Hypertension in children with congenital adrenal hyperplasia , 2016, Clinical endocrinology.

[11]  J. Blair,et al.  Is physiological glucocorticoid replacement important in children? , 2016, Archives of Disease in Childhood.

[12]  P. Lichtenstein,et al.  Congenital adrenal hyperplasia and risk for psychiatric disorders in girls and women born between 1915 and 2010: A total population study , 2015, Psychoneuroendocrinology.

[13]  A. Natarajan,et al.  Congenital adrenal hyperplasia in children – a survey on the current practice in the UK , 2015, Journal of pediatric endocrinology & metabolism : JPEM.

[14]  N. Krone,et al.  Current and novel approaches to children and young people with congenital adrenal hyperplasia and adrenal insufficiency. , 2015, Best practice & research. Clinical endocrinology & metabolism.

[15]  S. Hahner,et al.  Diagnosis and management of adrenal insufficiency. , 2015, The lancet. Diabetes & endocrinology.

[16]  W. Bonfig,et al.  Blood pressure, fludrocortisone dose and plasma renin activity in children with classic congenital adrenal hyperplasia due to 21‐hydroxylase deficiency followed from birth to 4 years of age , 2014, Clinical endocrinology.

[17]  A.O. Omisanjo,et al.  Evaluation of Five Formulae for Estimating Body Surface Area of Nigerian Children , 2014, Annals of medical and health sciences research.

[18]  H. Falhammar,et al.  Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2014, The Journal of clinical endocrinology and metabolism.

[19]  B. Walker,et al.  Treatment and health outcomes in adults with congenital adrenal hyperplasia , 2014, Nature Reviews Endocrinology.

[20]  A. Grossman,et al.  THERAPY OF ENDOCRINE DISEASE: Perspectives on the management of adrenal insufficiency: clinical insights from across Europe , 2013, European journal of endocrinology.

[21]  B. Mendonca,et al.  Mineralocorticoid replacement during infancy for salt wasting congenital adrenal hyperplasia due to 21-hydroxylase deficiency , 2013, Clinics.

[22]  W. Miller,et al.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. , 2011, Endocrine reviews.

[23]  W. Bonfig,et al.  Growth Pattern of Untreated Boys with Simple Virilizing Congenital Adrenal Hyperplasia Indicates Relative Androgen Insensitivity during the First Six Months of Life , 2010, Hormone Research in Paediatrics.

[24]  V. Montori,et al.  Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. , 2010, The Journal of clinical endocrinology and metabolism.

[25]  J. Connell,et al.  Health Status of Adults with Congenital Adrenal Hyperplasia: A Cohort Study of 203 Patients , 2010, The Journal of clinical endocrinology and metabolism.

[26]  M. Lombès,et al.  Physiological Partial Aldosterone Resistance in Human Newborns , 2009, Pediatric Research.

[27]  C. Tack,et al.  Unfavourable trends in cardiovascular and metabolic risk in paediatric and adult patients with congenital adrenal hyperplasia? , 2009, Clinical endocrinology.

[28]  P. Hindmarsh.  Management of the child with congenital adrenal hyperplasia. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[29]  W. Bonfig,et al.  Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty. , 2007, The Journal of clinical endocrinology and metabolism.

[30]  N. Krone,et al.  Congenital adrenal hyperplasia and P450 oxidoreductase deficiency , 2007, Clinical endocrinology.

[31]  G. Borm,et al.  Absence of increased height velocity in the first year of life in untreated children with simple virilizing congenital adrenal hyperplasia. , 2006, The Journal of clinical endocrinology and metabolism.

[32]  A. Lippman.  Adherence to medication. , 2005, The New England journal of medicine.

[33]  J. Popović,et al.  Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2005, Journal for specialists in pediatric nursing : JSPN.

[34]  A. Rostami-Hodjegan,et al.  Weight‐related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency , 2004, Clinical endocrinology.

[35]  H. Inada,et al.  Poor Response to Substitution Therapy with Cortisone Acetate in Patients with Congenital Adrenal Hyperplasia , 2004, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.

[36]  C. Polychronakos,et al.  Prednisolone in the treatment of adrenal insufficiency: a re-evaluation of relative potency. , 2003, The Journal of pediatrics.

[37]  M. V. van’t Hof,et al.  Growth inhibition by glucocorticoid treatment in salt wasting 21-hydroxylase deficiency: in early infancy and (pre)puberty. , 2003, The Journal of clinical endocrinology and metabolism.

[38]  P. Hindmarsh,et al.  Congenital adrenal hyperplasia due to 21-hydroxylase deficiency: alterations in cortisol pharmacokinetics at puberty. , 2001, The Journal of clinical endocrinology and metabolism.

[39]  P. Hindmarsh,et al.  Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. , 2001, The Journal of endocrinology.

[40]  S. Rivkees,et al.  Dexamethasone Treatment of Virilizing Congenital Adrenal Hyperplasia: The Ability to Achieve Normal Growth , 2000, Pediatrics.

[41]  G. Kaltsas,et al.  Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. , 1999, The Journal of clinical endocrinology and metabolism.

[42]  K. Polonsky,et al.  Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the evening than in the morning. , 1999, The Journal of clinical endocrinology and metabolism.

[43]  T. Howlett.  An Assessment of Optimal Hydrocortisone Replacement Therapy , 1997, Clinical endocrinology.

[44]  A. Wedell,et al.  Early growth is not increased in untreated moderately severe 21‐hydroxylase deficiency , 1995, Acta paediatrica.

[45]  G. Warne,et al.  A possible defect in the inter-conversion between cortisone and cortisol in prepubertal patients with congenital adrenal hyperplasia receiving cortisone acetate therapy , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[46]  P. Wood,et al.  Corticosteroid replacement therapy: twice or thrice daily? , 1989, Journal of the Royal Society of Medicine.

[47]  M. New,et al.  Congenital adrenal hyperplasia. , 1988, Biochemical Society transactions.

[48]  W. Miller.  Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. , 2002, The Journal of clinical endocrinology and metabolism.